Zhilin Xiao

Dr. Zhilin Xiao


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YLYi Luo
Yi Luo
LYLiu Yang
Liu Yang
XCXunJie Cheng
XunJie Cheng
YBYongPing Bai
YongPing Bai
ZXZhilin Xiao
Zhilin Xiao
The prevalence and progression of cardiovascular disease (CVD) are significantly influenced by low-grade chronic inflammation. Our aim was to investigate the association of blood-count-based inflammatory markers with atrial fibrillation (AF), heart failure (HF), and cardiovascular mortality. We utilized prospective follow-up data from the UK Biobank, including 334,674 individuals (aged between 39 and 70 years) free of HF and AF at baseline. The exposures were blood-count-based inflammatory markers, including neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), systemic immune-inflammation index (SII), aggregate index of systemic inflammation (AISI), and systemic inflammatory response index (SIRI), which were computed using leukocyte counts (lymphocytes, monocytes, and neutrophils). The primary outcomes were the occurrence of AF, HF and cardiovascular-related deaths. Cox proportional hazards models were employed to determine hazard ratios (HRs) and their 95% confidence intervals (CIs) for assessing the longitudinal association between inflammatory markers and the development of cardiovascular events. Survival analysis was illustrated using Kaplan–Meier curves with the occurrence of AF, HF and CVD mortality as the endpoint. There were 16,994 incidences of AF and 7342 incidences of HF over a median follow-up of 10.4 years (range, 2.4–12.1). Additionally, there were 3434 deaths from CVD causes. A higher risk of cardiovascular mortality was significantly associated with NLR, MLR, SIRI, AISI, and SII in multivariable adjusted models (HR 1.44, 95% CI 1.30–1.58; HR 1.46, 95% CI 1.31–1.61; HR 1.57, 95% CI 1.41–1.75; HR 1.57, 95% CI 1.41–1.73; and HR 1.36, 95% CI 1.24–1.49, respectively). Furthermore, our analysis revealed positive associations between NLR, MLR, SIRI, and AISI and the risk for AF (HR 1.18, 95% CI 1.13–1.24; HR 1.19, 95% CI 1.14–1.25; HR 1.22, 95% CI 1.16–1.27; and HR 1.08, 95% CI 1.03–1.13, respectively), and HF (HR 1.42, 95% CI 1.33–1.52; HR 1.28, 95% CI 1.19–1.37; HR 1.45, 95% CI 1.35–1.56; and HR 1.32, 95% CI 1.23–1.41, respectively). Furthermore, the SII demonstrated a positive association with HF (HR 1.24, 95% CI 1.16–1.32). However, the association with AF was not statistically significant (HR 1.01, 95% CI 0.97–1.06). In summary, our research provides preliminary evidence that blood cell indices associated with the systemic inflammatory response, may serve as potential biomarkers for the risk of developing AF, HF and CVD mortality. Additionally, it is likely that a systemic inflammatory-immune response existed before the clinical diagnosis. Identifying high-risk populations based on the levels of inflammatory markers could help reduce the risk of death and prevent the onset of AF and HF. Further investigation is warranted to determine whether reducing inflammatory markers causally improves cardiovascular outcomes.

21 May 2011 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
LFLi Fang
Li Fang
MCMei-Fang Chen
Mei-Fang Chen
ZXZhilin Xiao
Zhilin Xiao
YLYin Liu
Yin Liu
GYGuo-Long Yu
Guo-Long Yu
XXXiu-Mei Xie
Xiu-Mei Xie

1 December 2011 in Journal of Cardiovascular Pharmacology
Verified
Journal Article
Closed access
LFLi Fang
Li Fang
MCMei-Fang Chen
Mei-Fang Chen
ZXZhilin Xiao
Zhilin Xiao
GYGuo-Long Yu
Guo-Long Yu
XCXiao-Bin Chen
Xiao-Bin Chen
XXXiu-Mei Xie
Xiu-Mei Xie
Previous studies have demonstrated that endothelial progenitor cells (EPCs) could delay the progress of vascular remodeling in blood vessel–proliferating diseases. The proliferation of vascular smooth muscle cells (VSMCs) is a pivotal factor in cardiovascular diseases. In this study, we investigated whether EPCs could inhibit the Angiotensin II (Ang II)–induced proliferation of VSMCs. The effect of early EPC-conditioned medium (E-EPC-CM), late EPCs-CM (L-EPC-CM), and HUVEC-CM on Ang II–induced proliferation of VSMCs was assessed by BrdU incorporation, total protein content, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays, and flow cytometry. Reverse transcriptase–polymerase chain reaction and Western blot were performed to analyze the effect of different CMs on Ang II–induced phosphorylations of ERK, JNK, p38, and NF-κB subunit p65 and the expressions of c-myc and c-fos. E-EPC-CM, L-EPC-CM, and HUVEC-CM significantly inhibited the Ang II–induced DNA synthesis, total protein expression, cell survival, and cell cycle progress of VSMCs. Furthermore, E-EPC-CM significantly inhibited the Ang II–induced phosphorylation of ERK, JNK, p38, and p65 (nuclear translocation of p65) and the expressions of c-myc and c-fos. Taken together, these data suggested that EPCs may delay the progress of vascular remodeling in blood vessel–proliferating diseases by inhibiting Ang II–induced proliferation of VSMCs through inactivating MAPKs and NF-κB signaling pathways and by reducing the expressions of c-myc and c-fos.

29 July 2024 in International Immunopharmacology
Verified
Journal Article
Closed access
MYMei Yang
Mei Yang
XLXueting Liu
Xueting Liu
MJManli Jiang
Manli Jiang
JHJinyue Hu
Jinyue Hu
ZXZhilin Xiao
Zhilin Xiao

24 August 2018 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
XCXiaobin Chen
Xiaobin Chen
BXBolin Xiao
Bolin Xiao
MYMei Yang
Mei Yang
MCMeifang Chen
Meifang Chen
ZXZhilin Xiao
Zhilin Xiao

1 March 2025 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
ZXZhilin Xiao
Zhilin Xiao
XCXunjie Cheng
Xunjie Cheng
YBYongping Bai
Yongping Bai
Background: The identification of inflammatory genes linked to coronary artery disease (CAD) helps to enhance our understanding of the disease’s pathogenesis and facilitate the identification of novel therapeutic targets. Methods: Inflammation-related genes (IRGs) were downloaded from the Msigdb database. Differentially expressed genes (DEGs) were determined by comparing CAD group with the control group in the GSE113079 and GSE12288 datasets. Key module genes associated with CAD were identified through weighted gene co-expression network analysis (WGCNA). Differentially expressed IRGs (DE-IRGs) were established by intersecting the DEGs, key module genes, and IRGs. Feature genes were derived using machine learning techniques. Mendelian randomization (MR) analysis was conducted to explore the causal relationship between CAD and the identified feature genes. Subsequently, a logistic regression model and an alignment diagram model were developed to predict the incidence of CAD. Results: In the given datasets, a total of 92 DE-IRGs were identified. Furthermore, twelve feature genes were discerned utilizing four distinct machine learning algorithms. Notably, two pivotal genes, HIF1A (odds ratio (OR) = 1.031, P = 0.024) and TNFAIP3 (OR = 1.104, P = 0.007), exhibited a causal relationship with coronary artery disease (CAD). Additionally, logistic regression and alignment diagram models demonstrated their efficacy in predicting the incidence of CAD. Ultimately, TNFAIP3 and HIF1A were significantly associated with T-cell receptor and NOD-like receptor signaling pathways. Conclusion: The identification of TNFAIP3 and HIF1A as causal inflammatory biomarkers of CAD offers novel insights with significant clinical potential, which may provide valuable targets for the management and treatment of CAD.